PCNA和NDRG1在前列腺癌及良性前列腺增生组织中的表达及意义

发布时间：2018-05-31 05:14

本文选题：良性前列腺增生 + 前列腺癌　；参考：《延边大学》2014年硕士论文

【摘要】：目的：探讨良性前列腺增生及前列腺癌组织中肿瘤生物标记物PCNA和NDRG1的表达及意义。判定PCNA和NDRG1在前列腺癌中的表达与发生发展过程中的诊断价值。探讨联合检测PCNA和NDRG1对前列腺癌的诊断及意义。方法：收集延边大学附属医院2007-2012年期间治疗前列腺癌及良性前列腺增生住院病人共78例,其中良性前列腺增生病人11例为正常对照组。前列腺癌病人67例,并按病理Gleason评分又分为低分化组49例和高分化组18例；按肿瘤学TNM分期将前列腺癌分为T1期、T2期、T3期、T4期,其中T1期和T2期分为一组,T3期和T4期分别一组,并两组间进行比较；将前列腺癌按有无骨转移分别两组,并两组间进行比较。全部数据采用免疫组化学方法进行统计分析。结果： 1.PCNA在良性前列腺增生和前列腺癌中的阳性表达具有显著性差异,并有显著统计学意义(P0.05)。PCNA在前列腺癌高分化组与低分化组的阳性表达具有显著性差异,并有统计学意义(P0.05)；在肿瘤学TNM分期中T1～T2期总表达率与T3-T4期总表达具有显著性差异,并有统计学意义(P0.05)；PCNA在前列腺癌有骨转移和无骨转移组织中表达有显著性差异,具有统计学意义(P0.05)。 2.NDRG1在良性前列腺增生和前列腺癌中的阳性表达具有显著性差异,并有统计学意义(P0.05)。NDRG1在前列腺癌高分化组与低分化组的阳性表达却无显著性差异,无统计学意义(P0.05)；在肿瘤学TNM分期中NDRG1在T1-T2期总表达率与T3-T4期总表达率无显著性差异,并无统计学意义(P0.05)；PCNA在前列腺癌有骨转移和无骨转移组织中表达无显著性差异,并无统计学意义(P0.05)。 3.PCNA和NDRG1在良性前列腺增生及前列腺癌中表达呈负相关,并具有统计学意义(P0.05,r=-0.998)。结论： 1.PCNA在前列腺癌组织中的表达水平显著高于良性前列腺增生组织,随病理Gleason评分、TNM分期及有骨转移密的前列腺癌相关,提示PCNA是诊断前列腺癌的重要肿瘤生物标记物,其阳性表达程度代表肿瘤增殖活性、前列腺癌恶性程度及预后。 2.NDRG1在前列腺癌组织与良性前列腺增生组织中都呈现高表达,但良性前列腺增生组织中表达明显高于前列腺癌组织,与Gleason评分无显著性差异,但随Gleason评分增高有逐渐下降趋势。提示,NDRG1可望成为诊断前列腺癌的新的肿瘤生物标记物。但对于TNM分期及前列腺癌有无骨转移NDRG1的表达无差异。 3.PCNA和NDRG1在前列腺癌的发生发展都有较高的特异性和敏感度,联合检测PCNA和NDRGl可能提高前列腺癌诊断率。
[Abstract]:Objective: to investigate the expression and significance of tumor biomarkers PCNA and NDRG1 in benign prostatic hyperplasia and prostate cancer. To evaluate the expression of PCNA and NDRG1 in prostate cancer and its diagnostic value. To explore the diagnostic value of combined detection of PCNA and NDRG1 in prostate cancer. Methods: a total of 78 patients with prostate cancer and benign prostatic hyperplasia were collected from Yanbian University affiliated Hospital from 2007 to 2012. Among them, 11 patients with benign prostatic hyperplasia (BPH) were as normal control group. 67 cases of prostate cancer were divided into low differentiation group (49 cases) and well-differentiated group (18 cases) according to pathological Gleason score, and prostate cancer was divided into T 1 stage and T 2 stage T 3 stage and T 4 stage according to TNM stage of oncology, in which T 1 stage and T 2 stage were divided into 3 stage and T 4 stage, respectively. Prostate cancer was compared with or without bone metastasis. All the data were analyzed by immunohistochemical method. Results: The positive expression of 1.PCNA in benign prostatic hyperplasia (BPH) and prostate cancer was significantly different. There was a significant difference between the total expression rate of T1~T2 and that of T3-T4 in TNM stage of oncology, and there was significant difference in the expression of T1~T2 between bone metastases and no bone metastases in prostate cancer, and there was a significant difference in the expression of P0.05 and P0.05in the stage of oncology, and there was a significant difference in the expression of P0.05 and P0.05 in prostate cancer with and without bone metastasis. It has statistical significance (P 0.05). There was significant difference in the positive expression of 2.NDRG1 between benign prostatic hyperplasia and prostate cancer, and there was no significant difference in the positive expression of 2.NDRG1 between highly differentiated and poorly differentiated prostate cancer. There was no significant difference in the total expression rate of NDRG1 between T1-T2 stage and T3-T4 stage in TNM stage of oncology, and there was no significant difference in the expression of NDRG1 in bone metastases and no bone metastases of prostate cancer. There was no statistical significance (P 0.05). The expression of 3.PCNA and NDRG1 in benign prostatic hyperplasia (BPH) and prostate cancer was negatively correlated, and there was a significant difference between P0.05r-0.998G (P 0.05). Conclusion: The expression of 1.PCNA in prostate cancer was significantly higher than that in benign prostatic hyperplasia (BPH). The expression of PCNA was correlated with the pathological Gleason score and bone metastasized prostate cancer, suggesting that PCNA was an important tumor biomarker in the diagnosis of prostate cancer. Its positive expression level represents tumor proliferative activity, malignant degree and prognosis of prostate cancer. The expression of 2.NDRG1 in prostate cancer tissues and benign prostatic hyperplasia tissues was higher than that in prostate cancer tissues. There was no significant difference between 2.NDRG1 and Gleason score, but with the increase of Gleason score, the expression of 2.NDRG1 decreased gradually. These results suggest that NDR G 1 may be a new tumor biomarker for the diagnosis of prostate cancer. However, there was no difference in the expression of NDRG1 in TNM stage and prostate cancer with or without bone metastasis. Both 3.PCNA and NDRG1 have high specificity and sensitivity in the development of prostate cancer. Combined detection of PCNA and NDRGl may improve the diagnosis rate of prostate cancer.
【学位授予单位】：延边大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.25

【参考文献】